Mark Day

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH.

Purdue Pharma (Canada) manufactures and markets pharmaceutical products. It products for the treatment of pain, respiratory disease, gastrointestinal disorders, and infection control. The firm include laxatives, bronchodilators, antiseptics, and analgesics. Purdue Pharma is headquartered in Pickering, Canada

Part of Abbott Laboratories, Inc., the private company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL.